will semaglutide compound be banned What possible compounded ban means for patients Manufacturing copycat drugs that mimic
Description
J.MoncktonJ
[DOI] [PubMed] [Google Scholar] 118.Degn K.B., Juhl C.B., Sturis J., et al
Semaglutide is a GLP-1 receptor agonist that mimics the hormone glucagon-like peptide-1

This has led many patients to seek treatment through private prescribing, where eligibility criteria may differ and access is faster, albeit at personal cost
Atherosclerosis and GLP-1RA The clinical trials investigating the impact of GLP-1RA on cardiovascular health have shown that the incidence of MACE does not differ between the GLP-1R agonist and placebo groups until 1218 months after initiation of therapy, which aligns with the potential anti-atherogenic effect of GLP-1RA (Sattar et al

doi: 10.1155/2012/175245 22 Di ChiaraTLicataAArganoCDuroGCorraoSScaglioneR
